Compare
Market cap
—
P/E (TTM)
—
Forward P/E (NTM)
—
Forward P/S (NTM)
—
Rev growth (TTM)
—
YTD performance
—
52W performance
—
FCF yield
—
Market cap
$721M
P/E (TTM)
—
Forward P/E (NTM)
—
Forward P/S (NTM)
126.79x
Rev growth (TTM)
-17.9%
YTD performance
13.0%
52W performance
-38.1%
FCF yield
-21.8%
Add up to 1 more ticker to compare
Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.
Not enough overlapping price history for this window.
Market Cap
Enterprise Value
Price
P/E Ratio
P/S Ratio
EV/Sales
EV/EBITDA
P/B Ratio
P/FCF Ratio
EV/FCF
PEG Ratio
Forward P/E (NTM)
Forward P/S (NTM)
Revenue (TTM)
Revenue Growth (YoY)
Forward Rev Growth
Gross Margin (TTM)
Operating Margin (TTM)
EBITDA Margin (TTM)
Net Margin (TTM)
FCF Margin (TTM)
Net Income (TTM)
FCF (TTM)
EPS (TTM)
ROE (TTM)
ROA (TTM)
ROIC (TTM)
Cash
Debt
Net Cash/Debt
Current Ratio (TTM)
Quick Ratio (TTM)
Debt/Equity (TTM)
Debt/Assets (TTM)
Interest Coverage (TTM)
Net Debt/EBITDA (TTM)
Beta
52W Performance
YTD Performance
% from 52W High
% from 52W Low
Asset Turnover (TTM)
FCF Yield (TTM)
Earnings Yield (TTM)
Dividend Yield (TTM)
Rule of 40
EV/GP/RG
Metric | DRUG.CN | PRME |
|---|---|---|
Market & Valuation | ||
| Market Cap | $721M | |
| Enterprise Value | $673M | |
| Price | $3.99 | |
| P/E Ratio | N/A | |
| P/S Ratio | 176.94x | |
| EV/Sales | 165.29x | |
| EV/EBITDA | 0.00x | |
| P/B Ratio | 13.58x | |
| P/FCF Ratio | N/A | |
| EV/FCF | -4.29x | |
| PEG Ratio | N/A | |
| Forward P/E (NTM) | N/A | |
| Forward P/S (NTM) | 126.79x | |
Revenue & Growth | ||
| Revenue (TTM) | $4M | |
| Revenue Growth (YoY) | -17.9% | |
| Forward Rev Growth | 22.7% | |
Profitability | ||
| Gross Margin (TTM) | 0.0% | |
| Operating Margin (TTM) | 0.0% | |
| EBITDA Margin (TTM) | -4643.3% | |
| Net Margin (TTM) | -4613.1% | |
| FCF Margin (TTM) | -3850.9% | |
| Net Income (TTM) | $-188M | |
| FCF (TTM) | $-157M | |
| EPS (TTM) | -$1.06 | |
| ROE (TTM) | -18827.0% | |
| ROA (TTM) | -5911.0% | |
| ROIC (TTM) | -18827.0% | |
Financial Health | ||
| Cash | $47M | |
| Debt | $0 | |
| Net Cash/Debt | $47M | |
| Current Ratio (TTM) | 3.05x | |
| Quick Ratio (TTM) | 3.01x | |
| Debt/Equity (TTM) | 0.00x | |
| Debt/Assets (TTM) | 0.0% | |
| Interest Coverage (TTM) | N/A | |
| Net Debt/EBITDA (TTM) | 0.00x | |
Performance | ||
| Beta | 2.35 | |
| 52W Performance | -38.1% | |
| YTD Performance | 13.0% | |
| % from 52W High | -40.0% | |
| % from 52W Low | 49.4% | |
Efficiency & Yields | ||
| Asset Turnover (TTM) | 0.01x | |
| FCF Yield (TTM) | -21.8% | |
| Earnings Yield (TTM) | -26.1% | |
| Dividend Yield (TTM) | N/A | |
Other | ||
| Rule of 40 | -3,868.8 | |
| EV/GP/RG | N/A | |
| Ticker research | View DRUG.CN research | View PRME research |